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Abstract
Background: Although deleterious mutations in interleukin-10 and its receptor molecules cause severe infantile-onset
inflammatory bowel disease, there are no reports of mutations affecting this signaling pathway in Japanese patients.
Here we report a novel exonic mutation in the IL10RA gene that caused unique splicing aberrations in a Japanese
patient with infantile-onset of inflammatory bowel disease in association with immune thrombocytopenic purpura and
a transient clinical syndrome mimicking juvenile myelomonocytic leukemia.
Case presentation: A Japanese boy, who was the first child of non-consanguineous healthy parents, developed
bloody diarrhea, perianal fistula, and folliculitis in early infancy and was diagnosed with inflammatory bowel disease. He
also developed immune thrombocytopenic purpura and transient features mimicking juvenile myelomonocytic
leukemia. The patient failed to respond to various treatments, including elemental diet, salazosulfapyridine,
metronidazole, corticosteroid, infliximab, and adalimumab. We identified a novel mutation (c.537G > A, p.T179T) in
exon 4 of the IL10RA gene causing unique splicing aberrations and resulting in lack of signaling through the
interleukin-10 receptor. At 21 months of age, the patient underwent allogeneic hematopoietic stem cell transplantation
and achieved clinical remission.
Conclusions: We describe a novel exonic mutation in the IL10RA gene resulting in infantile-onset inflammatory bowel
disease. This mutation might also be involved in his early-onset hematologic disorders. Physicians should be familiar
with the clinical phenotype of IL-10 signaling defects in order to enable prompt diagnosis at an early age and referral
for allogeneic hematopoietic stem cell transplantation.
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Background
Interleukin-10 (IL-10), an anti-inflammatory cytokine,
binds to 2 receptors, namely 2 alpha molecules (IL-
10RA/IL-10R1) and 2 beta molecules (IL-10RB/IL-10R2)
[1, 2]. IL-10 signaling plays a key role in maintaining im-
mune homeostasis in the gastrointestinal tract. Accord-
ingly, defects of IL10, IL10RA, or IL10RB genes cause
very early-onset inflammatory bowel disease (IBD) includ-
ing infantile-onset IBD (IOIBD) [3–5]. Patients with muta-
tions in IL10 or IL10 receptor (IL10R) genes present with
severe colitis, perianal disease and folliculitis manifesting in
the first months of life. These patients are refractory to im-
munosuppressive therapies such as corticosteroids, metho-
trexate, thalidomide, and anti-tumor necrosis factor-alpha
(TNF-α) antibodies, yet, allogeneic hematopoietic stem cell
transplantation (HSCT) has been shown to be curative in
these conditions [3–5]. To date over 40 patients of various
ethnicities with IL10/IL10R deficiency have been reported
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[3–14]. However, reports on IL-10 signaling pathway de-
fects in the Japanese population are lacking. Here we
describe a Japanese IOIBD patient with a novel exonic
mutation in the IL10RA gene causing unique splicing
aberrations. Interestingly, this patient also developed im-
mune thrombocytopenic purpura (ITP) and transient ab-
normalities mimicking juvenile myelomonocytic leukemia
(JMML) in early infancy.
Case presentation
A Japanese boy was born by spontaneous vaginal delivery
at 41 weeks of gestation, with a birth weight of 2834 g. He
was the first child of non-consanguineous healthy parents.
At 2 months of age, he presented with hepatosplenome-
galy, purpura, leukocytosis (white blood cell count, 2.5 ×
1010 /L), monocytosis (monocytes, 2.0 × 109 /L), anemia
(hemoglobin, 87 g/L), and thrombocytopenia (platelets,
3.6 × 1010 /L). Bone marrow examination disclosed hyper-
cellularity without excessive blasts or abnormal appear-
ance of megakaryocytes. Cytogenetic analysis indicated a
normal male karyotype, and colony assay of bone marrow
mononuclear cells showed spontaneous colony formation
and high sensitivity to granulocyte-macrophage colony
stimulating factor. Genetic analysis revealed no reported
mutations in PTPN11, NRAS, KRAS, or CBL genes. While
his clinical manifestations met diagnostic criteria for
JMML [15], his symptoms and blood test results normal-
ized spontaneously.
At 6 months of age he developed bloody diarrhea,
perianal fistula, and folliculitis. Endoscopy showed ero-
sive changes, multiple aphthous ulcers, and longitudinal
ulcerations of the colon. Elevated C-reactive protein and
increased erythrocyte sedimentation rate suggested the
presence of a chronic inflammatory disorder. Immune
work-up was normal, including T and B lymphocytes
numbers, proliferative response of peripheral blood
mononuclear cells (PBMCs) to phytohemagglutinin,
serum immunoglobulin concentrations, neutrophil phago-
cytic capacity and microbicidal activity. The Wiskott-
Aldrich syndrome protein was expressed normally in
PBMCs.
Based on clinical, laboratory, and endoscopic findings,
the patient was diagnosed with Crohn’s disease, which was
treated with an elemental diet, salazosulfapyridine, metro-
nidazole, and a corticosteroid. At the same time, he again
developed thrombocytopenia (platelets, 3.2 × 1010 /L) and
was diagnosed with ITP since megakaryocytes in the bone
marrow were normal and platelet-associated immuno-
globulin G was elevated (90 ng/107 cells) [16]. Treatment
with high-dose intravenous immunoglobulin G led to
prompt normalization of platelets count, but did not lead
to any improvement in bloody diarrhea, fistula, or follicul-
itis. The patient also had recurrent fevers and was treated
with systemic antibiotics.
Given lack of colitis improvement, at 9 months of age, he
began treatment with infliximab (IFX), achieving partial re-
sponse of bloody diarrhea, perianal fistula, and folliculitis.
At the age of 14 months, adalimumab (ADA) was
substituted for IFX because of an allergic reaction to infu-
sions. From that point he was treated with a maintenance
regimen of ADA, an elemental diet, and salazosulfapyridine.
Growth and development then entered the normal range,
although bloody diarrhea and folliculitis persisted. Given
his clinical features, an IL-10 signaling defect was suspected
and targeted sequencing confirmed an IL10RA mutation.
At 21 months of age, the patient underwent allogeneic
HSCT using umbilical cord blood from a matched unre-
lated donor at Kyushu University Hospital, achieving rapid
and sustained complete chimerism and clinical remission.
Currently, at the age of 24 months, the patient is in sus-
tained clinical remission since 2 months after HSCT.
Identification of novel IL10RA mutation and IL-10 receptor
defect
To detect mutations of IL10RA and IL10RB, we per-
formed direct sequence analysis using genomic DNA
isolated from PBMCs from the patient and his parents
(see Additional files 1 and 2). We identified a novel
homozygous and heterozygous mutation (c.537G > A,
p.T179T) at the 3' end of exon 4 of IL10RA in the pa-
tient and his parents, respectively (Fig. 1a). Because the
nucleotides at the end of the exon are involved in the
splicing process, we examined whether the c.537G > A
mutation generated splicing variants by reverse-
transcription polymerase chain reaction (RT-PCR) ana-
lysis using 3 primer sets: set A, to amplify exons 2 and 3
as a control; set B, to detect deletion or insertion near
the boundary between exons 4 and 5; and set C, to amp-
lify exons 3 and 4 (upper panel in Fig. 1b). We detected
an additional small PCR product in the patient, as well
as the product of expected size using set B (compare
band #3 with #2, lower panel in Fig. 1b). Moreover, we
found a much smaller product in the patient using set C
(band #4, lower panel in Fig. 1b). These results sug-
gested that the exonic c.537G > A mutation generated at
least 2 abnormal transcripts of the IL10RA gene. We fur-
ther investigated the nucleotide sequence of these PCR
products. As shown in Fig. 1c, product #2, which showed
expected size, possessed a c.537G >A mutation but indi-
cated intact splicing between exon 4 and 5. However,
product #3 showed an 18-base deletion at the 3' end of
exon 4, which was generated by activation of a nearby
cryptic splice donor site. This 18-base deletion was pre-
dicted to cause loss of 6 amino acids (174-VPGNFT-179)
from the IL-10RA molecule. Moreover, product #4 showed
complete deletion of exon 4 (170 bases). This exon 4
skipping caused a frameshift, with translational arrest at a
site 7 amino acids distant. Thus, the exonic c.537G >A
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mutation induced aberrant splicing in the IL10RA gene,
which would cause loss of function.
To determine whether the novel mutation identified in
the patient resulted in defective signaling function in-
volving the IL-10R, PBMCs obtained from the patient
were compared with those from his father, who served
as a healthy control. Cells were stimulated with IL-10 as
previously described [13] (see Additional file 3). IL-10
stimulation of the patient’s PBMCs failed to induce
phosphorylation of signal transducer and activator of
transcription 3 (pSTAT3), which is a key transcription
factor downstream of the IL-10R. IL-6-induced pSTAT3,
which served as an internal positive control, was intact
(right panel in Fig. 2). In contrast, both IL-10 stimula-
tion and IL-6 stimulation of the control cells led to
pSTAT3 formation (left panel in Fig. 2). These results
suggest that the mutation resulted in loss of normal
function of the IL-10R.
Discussion
Loss of function of IL-10 and IL-10R molecules causes
refractory colitis with folliculitis and perianal disease,
manifesting very early in infancy [3–5]. Here we report a
Japanese IOIBD patient with a novel exonic mutation
(c.537G > A, p.T179T) in exon 4 of the IL10RA gene that
produced uniquely abnormal transcripts. Also in early
infancy, the patient developed ITP and a transient clin-
ical syndrome with features mimicking JMML.
From early infancy, the patient manifested refractory
colitis, perianal disease and folliculitis, in addition to as-
sociated hematologic disorders, which may also be the
result of the IL10RA genetic defect. Expression of IL-10
in PBMCs has been reported to correlate to some extent
with disease activity in children with chronic active ITP
[17]. IL-10 normally exerts negative feedback control
that limits activation of Th1 cells as well as monocytes
and macrophages [18]. In vitro, IL-10 has been found to
inhibit cell growth and granulocyte/macrophage colony
stimulating factor production in chronic myelomonocy-
tic leukemia cells, as well as inhibiting cytokine produc-
tion and growth in JMML cells [19, 20]. Neven et al and
Shouval et al reported that patients with IL-10R defi-
ciency tend to develop non-Hodgkin B-cell lymphomas
[13, 21]. These findings suggest that IL-10 signaling de-
fects might lead not only to development of lymphoma
but also to ITP and JMML-like states. However, there is
a possibility that there may be another gene involved
here as the remainder of this patient’s genes have not
been tested.
We identified a point mutation, c.537G > A, in the
exon adjacent to a splice donor site whose consensus se-
quence is MAG|GURAGU (M represents A or C, while
R represents a purine), extending from position -3 to
position +6 relative to the exon–intron junction. Within
the consensus sequence, mutations affecting GU resi-
dues at positions +1 and +2 are most common followed
by mutations at position +5 [22]. In our patient, a
Fig. 1 Identification of the IL10RA mutation associated with infantile-onset inflammatory bowel disease (IOIBD). a A c.537G > A mutation at the 3'
end of exon 4 of the IL10RA gene in the family of our patient with IOIBD. Arrows indicate site of mutation. Parts of sequences of exon 4 and
intron 4 are shown in upper case and lower case, respectively. b RT-PCR analysis for the IL10RA gene in the patient with c.537G > A mutation.
Schematic representation of positions of the primers for RT-PCR and the c.537G > A mutation is given in the upper panel. RT-PCR products from
the c.537G > A mutation of the IL10RA gene are shown in the lower panel. The expected 216-bp and 495-bp products of the IL10RA exons 4-5
and exons 2-5, respectively, were detected in a healthy control and the patient, while additional shorter products were observed in the patient
(bands 3 and 4). c Sequence analysis of RT-PCR products indicated that the c.537G > A mutation caused 2 kinds of splicing variants; an 18 bp
deletion of the 3' end of exon 4 and skipping of exon 4 (170 bp)
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relatively rare -1G > -1A homozygous mutation re-
sulted in aberrant splicing manifest as disease. The
AG|GURAGU motif is recognized by the U1 small
nuclear ribonucleoprotein (snRNP) to define the
exon-intron boundary in the first step of splicing
process [23]. When the motif is changed, U1 snRNP
would not recognize the exon-intron junction prop-
erly and would bind to other regions with similar se-
quence. In the exon 4 of IL10RA, there is
AGGTGCCA sequence at 18 bases upstream of exon
4-intron 4 boundary where c.537G > A is located. This
sequence might be recognized by U1 snRNP, and the
splicing variant of 18-base deletion at the 3' end of
exon 4 was generated in our patient. However, the
AGGTGCCA sequence in exon 4 is not completely
matched to the conserved AGGURAGU motif, so that
another splicing variant, exon 4 skipping, might occur
alternatively. This type of splicing aberration is not
specific to the case in this study because we obtained
similar results in the patients affected with familial
hemophagocytic lymphohistiocytosis previously [24, 25].
According to the database which predicts splice-altering
single nucleotide variants (dbscSNV: https://www.solve
bio.com/library/dbscSNV), the IL10RA c.537G >A substi-
tution shows high probability of affecting splicing (the
Ada score = 0.99996). This in silico analysis strongly sup-
ports our results that the c.537G >A mutation generated
splicing variants. Although the c.537G > A nucleotide
change is not found in the three databases (1000
Genome: http://www.1000genomes.org/, ExAC: http://
exac.broadinstitute.org/, or NHLBI Exome Variant Ser-
ver: http://evs.gs.washington.edu/EVS/), the frequency of
this variant is shown to be 0.0019 in the Human Genetic
Variation Database which contains genetic variations de-
termined by exome sequencing of 1208 Japanese (http://
www.genome.med.kyoto-u.ac.jp/SnpDB/). This suggests
that the c.537G >A mutation would be detected in other
Japanese IOIBD patients in future.
The c.537G > A mutation caused an in-frame deletion
of 18 bp of exon 4 in the IL10RA gene that leads to loss
of 6 amino acids (174-VPGNFT-179). Structural analysis
of the IL-10/IL-10RA/IL-10RB complex suggests that
these amino acids compose a hydrophobic area that
could importantly influence crucial interactions with IL-
10RB molecules [26]. Because sequential assembly of
IL10-RA and IL-10RB is required for IL-10 cellular re-
sponse [27], disruption of stable interactions between
these molecules could lead to a loss of IL-10 signaling,
resulting in IOIBD in our patient. Although we also
identified the normal splicing PCR product in our pa-
tient, we speculated that the normal splicing produces a
small amount of IL-10RA and cannot rescue the IL-10
signaling in his macrophages and T cells.
Conclusions
We identified a novel exonic mutation (c.537G > A,
p.T179T) in the IL10RA gene that caused unique spli-
cing aberrations likely to lead to IOIBD. IL-10R genetic
defects also might be involved in hematologic disorders
during infancy such as ITP and JMML-like disorders.
Physicians should be familiar with the clinical phenotype
of IL-10 signaling defects in order to enable prompt
diagnosis at an early age and referral for allogeneic
HSCT, before later complication occur, such as develop-
ment of lymphoma.
Consent
Written informed consent was obtained from the pa-
tient’s parents for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor of this journal. This
study was approved by the Institutional Review Board at
Kurume University, Japan and the Boston Children’s
Hospital, MA.
Fig. 2 Loss of function of the IL-10 receptor. Functional analysis of IL-10 receptor complex was performed by determining signal transducer and
activator of transcription 3 (STAT3) phosphorylation using flow cytometry. Peripheral blood mononuclear cells from the patient (right panel) and
his father (left panel) were stimulated for 15 minutes with IL-10 (20 ng/mL) or IL-6 (20 ng/mL) or kept unstimulated, and later fixed, permeabilized
and stained for phosphorylated STAT3 (pSTAT3), which is downstream of the IL-10 and IL-6 receptor complexes
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